Skip to main content

Table 2 Immunosuppressive/antiproliferative and vasoactive agents administered anytime during disease course in a multicentre systemic sclerosis cohort

From: Treatment modalities and drug survival in a systemic sclerosis real-life patient cohort

 Total (n = 497)Diffuse (n = 243)Limited (n = 254)p
Immunosuppresives/ antiproliferatives
 Methotrexate265 (53%)134 (55%)131 (52%)NS
 Cyclophosphamide130 (26%)97 (40%)33 (13%)0.021
 Mycophenolate58 (12%)36 (15%)22 (9%)0.068
 Azathiorine52 (10.5%)27 (11%)25 (10%)NS
 Rituximab43 (9%)34 (14%)9 (4%)0.001
 Tocilizumab25 (5%)14 (6%)11 (4%)NS
Vasoactives
 Calcium channel blockers338 (68%)172 (71%)166 (65%)NS
 Bosentan164 (33%)104 (43%)60 (24%)0.001
 Abrisentan13 (3%)7 (3%)6 (2%)NS
 Macitentan9 (2%)3 (1%)6 (2%)NS
 Sildenafil34 (7%)23 (9%)11 (4%)0.05
 Iloprost33 (7%)18 (7%)15 (6%)NS
 Only immunosuppressive treatment209 (42%)96 (40%)113 (45%)NS
 Only vasoactive treatment39 (8%)20 (8%)19 (7%)NS
 Both treatments156 (31%)102 (42%)54 (21%)0.001
 No treatment93 (19%)25 (10%)68 (27%)0.001
  1. All data are shown as numbers (percentage)
  2. Mean disease duration: 11.8 ± 8.4 years, (mean + standard deviation)